Baseline characteristics at presentation for newly diagnosed patients and for patients at EOT
| . | Before treatment initiation (n = 173) . | End of first-line treatment (n = 82) . |
|---|---|---|
| Age in years, median (range) | 64 (40-88) | 61 (43-77) |
| Male sex, n (%) | 112 (65) | 56 (68) |
| No. of involved organs | ||
| Median (range) | 2 (1-4) | 2 (1-4) |
| Cardiac involvement | 128 (74%) | 42 (51%) |
| Renal involvement | 90 (52%) | 51 (62%) |
| Peripheral/autonomic neuropathy | 48 (28%) | 17 (26%) |
| Liver involvement | 29 (17%) | 10 (12%) |
| GI involvement | 19 (11%) | 6 (9%) |
| λ restriction, n (%) | 125 (72) | 55 (67) |
| dFLC (mg/dL), median (range) | 24.8 (0.2-1498) | 20.9 (0.7-1498) |
| Monotypic PCs percentage, median (range) | ||
| By MFC | 2.3 (0-41.8) | 2 (0-41.8) |
| By aspiration/biopsy | 10 (3-80) | 10 (2-80) |
| 2004 Mayo stage, n (%) | ||
| I | 39 (22) | 37 (45) |
| II | 67 (39) | 32 (39) |
| III | 67 (39) | 13 (16) |
| 2012 Mayo stage, n (%) | N = 172 | |
| I | 43 (25) | 34 (42) |
| II | 40 (23) | 27 (33) |
| III | 38 (22) | 6 (7) |
| IV | 51 (30) | 15 (18) |
| FISH abnormalities, n (%)* | N = 147 | N = 70 |
| t (11;14) | 83 (56) | 35 (50) |
| del (13q) | 60 (41) | 28 (40) |
| Any trisomy(ies) | 46 (31) | 17 (24) |
| First-line treatment, n (%) | ||
| ASCT | 65 (38) | 69 (84) |
| Bortezomib-based | 74 (43) | 10 (12) |
| Melphalan-based | 18 (10) | 3 (4) |
| IMiD-based | 2 (1) | — |
| No treatment | 8 (5) | — |
| Unknown | 6 (3) | — |
| . | Before treatment initiation (n = 173) . | End of first-line treatment (n = 82) . |
|---|---|---|
| Age in years, median (range) | 64 (40-88) | 61 (43-77) |
| Male sex, n (%) | 112 (65) | 56 (68) |
| No. of involved organs | ||
| Median (range) | 2 (1-4) | 2 (1-4) |
| Cardiac involvement | 128 (74%) | 42 (51%) |
| Renal involvement | 90 (52%) | 51 (62%) |
| Peripheral/autonomic neuropathy | 48 (28%) | 17 (26%) |
| Liver involvement | 29 (17%) | 10 (12%) |
| GI involvement | 19 (11%) | 6 (9%) |
| λ restriction, n (%) | 125 (72) | 55 (67) |
| dFLC (mg/dL), median (range) | 24.8 (0.2-1498) | 20.9 (0.7-1498) |
| Monotypic PCs percentage, median (range) | ||
| By MFC | 2.3 (0-41.8) | 2 (0-41.8) |
| By aspiration/biopsy | 10 (3-80) | 10 (2-80) |
| 2004 Mayo stage, n (%) | ||
| I | 39 (22) | 37 (45) |
| II | 67 (39) | 32 (39) |
| III | 67 (39) | 13 (16) |
| 2012 Mayo stage, n (%) | N = 172 | |
| I | 43 (25) | 34 (42) |
| II | 40 (23) | 27 (33) |
| III | 38 (22) | 6 (7) |
| IV | 51 (30) | 15 (18) |
| FISH abnormalities, n (%)* | N = 147 | N = 70 |
| t (11;14) | 83 (56) | 35 (50) |
| del (13q) | 60 (41) | 28 (40) |
| Any trisomy(ies) | 46 (31) | 17 (24) |
| First-line treatment, n (%) | ||
| ASCT | 65 (38) | 69 (84) |
| Bortezomib-based | 74 (43) | 10 (12) |
| Melphalan-based | 18 (10) | 3 (4) |
| IMiD-based | 2 (1) | — |
| No treatment | 8 (5) | — |
| Unknown | 6 (3) | — |
ASCT, autologous stem cell transplantation; dFLC, difference between involved and uninvolved light chains; FISH, fluorescence in situ hybridization; GI, gastrointestinal; IMiDs, immunomodulatory drugs.
Patients may have more than one abnormality.